Menelaos Zafrakas1, Panayiota Papasozomenou1, Christos Emmanouilides1. 1. Menelaos Zafrakas, Panayiota Papasozomenou, Research Laboratory for Mastology, Gynecology and Obstetrics, School of Health and Medical Care, Alexander Technological Institute of Thessaloniki, 57400 Thessaloniki, Greece.
Abstract
AIM: To evaluate the current role of sorafenib, an oral multikinase inhibitor in the treatment of breast cancer. METHODS: An extensive search of the literature until March 2016 was carried out in Medline and clinicaltrials.gov, by using the search terms "sorafenib" and "breast cancer". Papers found were checked for further relevant publications. Overall, 21 relevant studies were found, 18 in advanced breast cancer (16 in stage IV and two in stages III-IV) and three in early breast cancer. RESULTS: Among studies in advanced breast cancer, there were two trials with sorafenib as monotherapy, four trials of sorafenib in combination with taxanes, two in combination with capecitabine, one with gemcitabine and/or capecitabine, one with vinorelbine, one with bevacizumab, one with pemetrexed and one with ixabepilone, three trials of sorafenib in combination with endocrine therapy and two trials in women with brain metastases undergoing whole brain radiotherapy. In addition, there was one trial of sorafenib added to standard chemotherapy in the adjuvant setting, and two trials in the neoadjuvant setting. In general, sorafenib was well tolerated in breast cancer patients, though its dosage had to be adjusted in some trials, and discontinuation rates were high, particularly for the combination of sorafenib with anastrozole. Sorafenib monotherapy and combinations with taxanes, bevacizumab and ixabepilone showed inadequate efficacy, while efficacy results from combinations with gemcitabine and/or capecitabine and possibly tamoxifen were more promising. CONCLUSION: At present, sorafenib should not be used for the treatment of breast cancer outside of clinical trials and more clinical data are needed in order to support its standard use in breast cancer therapy.
AIM: To evaluate the current role of sorafenib, an oral multikinase inhibitor in the treatment of breast cancer. METHODS: An extensive search of the literature until March 2016 was carried out in Medline and clinicaltrials.gov, by using the search terms "sorafenib" and "breast cancer". Papers found were checked for further relevant publications. Overall, 21 relevant studies were found, 18 in advanced breast cancer (16 in stage IV and two in stages III-IV) and three in early breast cancer. RESULTS: Among studies in advanced breast cancer, there were two trials with sorafenib as monotherapy, four trials of sorafenib in combination with taxanes, two in combination with capecitabine, one with gemcitabine and/or capecitabine, one with vinorelbine, one with bevacizumab, one with pemetrexed and one with ixabepilone, three trials of sorafenib in combination with endocrine therapy and two trials in women with brain metastases undergoing whole brain radiotherapy. In addition, there was one trial of sorafenib added to standard chemotherapy in the adjuvant setting, and two trials in the neoadjuvant setting. In general, sorafenib was well tolerated in breast cancerpatients, though its dosage had to be adjusted in some trials, and discontinuation rates were high, particularly for the combination of sorafenib with anastrozole. Sorafenib monotherapy and combinations with taxanes, bevacizumab and ixabepilone showed inadequate efficacy, while efficacy results from combinations with gemcitabine and/or capecitabine and possibly tamoxifen were more promising. CONCLUSION: At present, sorafenib should not be used for the treatment of breast cancer outside of clinical trials and more clinical data are needed in order to support its standard use in breast cancer therapy.
Entities:
Keywords:
BRAF; Breast cancer; Kinase inhibitors; Mitogen-activated protein kinase; Sorafenib
Authors: A S Coates; E P Winer; A Goldhirsch; R D Gelber; M Gnant; M Piccart-Gebhart; B Thürlimann; H-J Senn Journal: Ann Oncol Date: 2015-05-04 Impact factor: 32.976
Authors: José Baselga; José Getúlio Martins Segalla; Henri Roché; Auro Del Giglio; Hélio Pinczowski; Eva M Ciruelos; Sebastião Cabral Filho; Patricia Gómez; Brigitte Van Eyll; Begoña Bermejo; Antonio Llombart; Bernardo Garicochea; Miguel Ángel Climent Durán; Paulo Marcelo Gehm Hoff; Marc Espié; Andre Augusto Junior Gemeinder de Moraes; Ronaldo Albuquerque Ribeiro; Clarissa Mathias; Miguel Gil Gil; Belén Ojeda; Josefa Morales; Sunhee Kwon Ro; Shell Li; Frederico Costa Journal: J Clin Oncol Date: 2012-03-12 Impact factor: 44.544
Authors: Denise A Yardley; Natalie Dickson; David Drosick; Chris Earwood; Roger Inhorn; Patrick Murphy; John D Hainsworth Journal: Clin Breast Cancer Date: 2016-02-12 Impact factor: 3.225
Authors: Suleiman Massarweh; Jessica Moss; Chi Wang; Edward Romond; Stacey Slone; Heidi Weiss; Rouzan G Karabakhtsian; Dana Napier; Esther P Black Journal: Future Oncol Date: 2014-12 Impact factor: 3.404
Authors: Thehang Luu; Paul Frankel; Cathie Chung; Warren Chow; Joanne Mortimer; Arti Hurria; George Somlo Journal: Clin Breast Cancer Date: 2013-10-26 Impact factor: 3.225
Authors: Scott M Wilhelm; Christopher Carter; Liya Tang; Dean Wilkie; Angela McNabola; Hong Rong; Charles Chen; Xiaomei Zhang; Patrick Vincent; Mark McHugh; Yichen Cao; Jaleel Shujath; Susan Gawlak; Deepa Eveleigh; Bruce Rowley; Li Liu; Lila Adnane; Mark Lynch; Daniel Auclair; Ian Taylor; Rich Gedrich; Andrei Voznesensky; Bernd Riedl; Leonard E Post; Gideon Bollag; Pamela A Trail Journal: Cancer Res Date: 2004-10-01 Impact factor: 13.312
Authors: Alfeu Zanotto-Filho; Subapriya Rajamanickam; Eva Loranc; V Pragathi Masamsetti; Aparna Gorthi; July Carolina Romero; Sonal Tonapi; Rosangela Mayer Gonçalves; Robert L Reddick; Raymond Benavides; John Kuhn; Yidong Chen; Alexander J R Bishop Journal: Cancer Lett Date: 2018-03-30 Impact factor: 8.679
Authors: Agnieszka Karbownik; Katarzyna Sobańska; Tomasz Grabowski; Joanna Stanisławiak-Rudowicz; Anna Wolc; Edmund Grześkowiak; Edyta Szałek Journal: Cancer Chemother Pharmacol Date: 2020-05-11 Impact factor: 3.333
Authors: Bruna R Silva; Rita Rebelo; Juliana M Rodrigues; Cristina P R Xavier; M Helena Vasconcelos; Maria-João R P Queiroz Journal: Molecules Date: 2021-03-13 Impact factor: 4.411